NRx Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for NRx Pharmaceuticals, Inc. (NRXP) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-25.13-30.15-39.75-93.06-51.78
Depreciation & Amortization0.010.010.000.000.00
Stock Based Compensation0.520.393.637.790.73
Change in Working Capital5.295.160.70-4.903.45
Change in Accounts Receivable0.000.000.000.83-0.83
Change in Accounts Payable-5.222.66-1.61-0.021.18
Change in Other Working Capital10.512.96-4.08-5.713.10
Other Operating Activities7.772.96-0.7052.4745.31
Net Cash from Operating Activities-10.64-21.66-39.76-37.70-2.27
Investing Activities
Capital Expenditures0.000.000.01-0.010.00
Net Cash from Investing Activities0.000.00-0.01-0.010.00
Financing Activities
Debt Repayment-8.58-4.04-0.52-1.280.00
Common Stock Issued5.918.1222.7053.682.58
Other Financing Activities3.070.0022.7011.050.00
Net Cash from Financing Activities7.496.2032.2163.463.25
Summary
Net Change in Cash-3.15-15.46-7.5525.750.98
Cash at Beginning of Period4.6020.0527.611.860.00
Cash at End of Period1.444.6020.0527.610.00
Free Cash Flow-10.64-21.66-39.77-37.71-2.27
Supplemental Disclosures
Interest Paid0.370.890.000.000.00